PMID- 37175785
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 9
DP  - 2023 Apr 29
TI  - Investigation into the Potential Role of Propionibacterium freudenreichii in 
      Prevention of Colorectal Cancer and Its Effects on the Diversity of Gut 
      Microbiota in Rats.
LID - 10.3390/ijms24098080 [doi]
LID - 8080
AB  - Colorectal cancer (CRC) accounts for 10% of all cancer diagnoses and 
      cancer-related deaths worldwide. Over the past two decades, several studies have 
      demonstrated the clinical benefits of probiotic supplementation and some studies 
      have shown that certain probiotics can modulate immunity and strengthen gut 
      microbiota diversity. This study aims to assess the impact of the 
      Propionibacterium freudenreichii (PF) probiotic against CRC induced by 
      azoxymethane (AOM), and to investigate its effects on gut microbiota diversity in 
      rats, as well as to evaluate the anti-proliferative activities of PF in HCT116 
      CRC cells. This experiment was performed using four groups of SD rats: normal 
      control, AOM group, PF group (1 x 10(9) CFU/mL), and standard drug control 
      (5-fluorouracil, 35 mg/kg). Methylene blue staining of colon tissues showed that 
      the administration of PF significantly reduced the formation of colonic aberrant 
      crypt foci (ACF) compared to the AOM control group. In addition, treated rats had 
      lower levels of malondialdehyde in their colon tissue homogenates, indicating 
      that lipid peroxidation was suppressed by PF supplementation. Furthermore, 16S 
      rRNA gene analysis revealed that probiotic treatment enhanced the diversity of 
      gut microbiota in rats. In vitro study showed that the viability of HCT116 cells 
      was inhibited by the probiotic cell-free supernatant with an IC(50) value of 13.3 
      +/- 0.133. In conclusion, these results reveal that consuming PF as probiotic 
      supplements modulates gut microbiota, inhibits the carcinogenic effects of AOM, 
      and exerts anti-proliferative activity against CRC cells. Further studies are 
      required to elucidate the role of PF on the immune response during the 
      development and growth of CRC.
FAU - Dikeocha, Ifeoma Julieth
AU  - Dikeocha IJ
AUID- ORCID: 0000-0003-1700-828X
AD  - Faculty of Medicine, University of Cyberjaya, Persiaran Bestari, Cyberjaya 63000, 
      Malaysia.
FAU - Al-Kabsi, Abdelkodose Mohammed
AU  - Al-Kabsi AM
AUID- ORCID: 0000-0003-0660-6049
AD  - Faculty of Medicine, University of Cyberjaya, Persiaran Bestari, Cyberjaya 63000, 
      Malaysia.
FAU - Ahmeda, Ahmad Faheem
AU  - Ahmeda AF
AUID- ORCID: 0000-0001-5962-9573
AD  - Department of Basic Medical Sciences, College of Medicine, Ajman University, 
      Ajman P.O. Box 346, United Arab Emirates.
AD  - Center of Medical and Bio-Allied Health Sciences Research, Ajman University, 
      Ajman P.O. Box 346, United Arab Emirates.
FAU - Mathai, Michael
AU  - Mathai M
AD  - College of Health and Biomedicine, Victoria University, Melbourne, VIC 3011, 
      Australia.
FAU - Alshawsh, Mohammed Abdullah
AU  - Alshawsh MA
AUID- ORCID: 0000-0001-8342-5183
AD  - Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 
      50603, Malaysia.
LA  - eng
GR  - ST015-2020/University of Malaya/
GR  - CRG/01/02/2020/Cyberjaya University/
PT  - Journal Article
DEP - 20230429
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (RNA, Ribosomal, 16S)
RN  - MO0N1J0SEN (Azoxymethane)
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Propionibacterium freudenreichii
MH  - *Gastrointestinal Microbiome
MH  - RNA, Ribosomal, 16S/genetics
MH  - Rats, Sprague-Dawley
MH  - Azoxymethane/adverse effects
MH  - *Colorectal Neoplasms/microbiology
PMC - PMC10179204
OTO - NOTNLM
OT  - Propionibacterium freudenreichii
OT  - azoxymethane
OT  - colorectal cancer
OT  - microbiome
OT  - probiotics
COIS- The authors declare no conflict of interest.
EDAT- 2023/05/13 15:12
MHDA- 2023/05/15 11:42
PMCR- 2023/04/29
CRDT- 2023/05/13 01:29
PHST- 2022/12/31 00:00 [received]
PHST- 2023/02/19 00:00 [revised]
PHST- 2023/02/21 00:00 [accepted]
PHST- 2023/05/15 11:42 [medline]
PHST- 2023/05/13 15:12 [pubmed]
PHST- 2023/05/13 01:29 [entrez]
PHST- 2023/04/29 00:00 [pmc-release]
AID - ijms24098080 [pii]
AID - ijms-24-08080 [pii]
AID - 10.3390/ijms24098080 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Apr 29;24(9):8080. doi: 10.3390/ijms24098080.